Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test
Context: Trends in epidermal growth factor receptor (EGFR) mutation based on ethnicity assist the initial selection of targeted therapy regimen. Reported incidence of EGFR mutation in Indian NSCLC patients is variable, ranging from 22% to 51.8%. Aim and Settings and Design: This multicent...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical Publishers, Inc.
2017-01-01
|
| Series: | Asian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/ASJO.ASJO_104_16 |
| _version_ | 1818990310505578496 |
|---|---|
| author | Kumar Prabhash Amit Rauthan Senthil Rajappa Chirag Desai Rajesh Mistry Amit Dutt Anuradha Chougule Ravi Mohan Pratap K Das Rajiv Kumar Vanita Noronha Amit Joshi Vijay M Patil Binay Swarup Anil Kukreja |
| author_facet | Kumar Prabhash Amit Rauthan Senthil Rajappa Chirag Desai Rajesh Mistry Amit Dutt Anuradha Chougule Ravi Mohan Pratap K Das Rajiv Kumar Vanita Noronha Amit Joshi Vijay M Patil Binay Swarup Anil Kukreja |
| author_sort | Kumar Prabhash |
| collection | DOAJ |
| description | Context: Trends in epidermal growth factor receptor (EGFR) mutation based on ethnicity assist the initial selection of targeted therapy regimen. Reported incidence of EGFR mutation in Indian NSCLC patients is variable, ranging from 22% to 51.8%.
Aim and Settings and Design: This multicenter, noninterventional study evaluated the prevalence of EGFR mutation in Indian NSCLC patients, its association with patients’ demographics, and for the first time used a central laboratory for molecular testing.
Subjects and Methods: Tissue samples from 252 NSCLC patients were tested at a Central Laboratory at Tata Memorial Hospital. Statistical Analysis Used: Patient demographics, baseline characteristics including smoking status from routine examination were recorded in a single visit. Chi-square or Fisher's exact test was used for association of EGFR mutation status with gender, age, smoking status, and histological subtypes.
Results: The prevalence of EGFR mutation in Indian NSCLC patients was 23.4%. Among these, 55.9% patients had mutations in exon 19, 39% in exon 21, and 1.7% in exon 18. The incidence of EGFR mutation was higher in females than males (32.5% vs. 18.9%, respectively), and in 30.6% patients that had never smoked, 26.3% smokers, and 5.8% former smokers. The mean duration of transportation of tissue samples to the central laboratory was 48 h with an average turnaround time of 5 days for molecular testing.
Conclusions: Molecular testing at a central laboratory is a feasible option in India. Prevalence of EGFR mutation in Indian NSCLC patients was similar across western and southern centers in India. A statistically significant association between EGFR mutation and gender as well as the smoking status of the patients was observed. Majority of the patients had in-frame deletions in exon 19. |
| first_indexed | 2024-12-20T19:52:20Z |
| format | Article |
| id | doaj.art-f5135b574d6941d59c58056871d0a86e |
| institution | Directory Open Access Journal |
| issn | 2454-6798 2455-4618 |
| language | English |
| last_indexed | 2024-12-20T19:52:20Z |
| publishDate | 2017-01-01 |
| publisher | Thieme Medical Publishers, Inc. |
| record_format | Article |
| series | Asian Journal of Oncology |
| spelling | doaj.art-f5135b574d6941d59c58056871d0a86e2022-12-21T19:28:16ZengThieme Medical Publishers, Inc.Asian Journal of Oncology2454-67982455-46182017-01-01030103904410.4103/ASJO.ASJO_104_16Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular testKumar Prabhash0Amit Rauthan1Senthil Rajappa2Chirag Desai3Rajesh Mistry4Amit Dutt5Anuradha Chougule6Ravi Mohan7Pratap K Das8Rajiv Kumar9Vanita Noronha10Amit Joshi11Vijay M Patil12Binay Swarup13Anil Kukreja14Department of Medical Oncology, Tata Memorial Hospital, Dr. Ernest Borges Marg, Mumbai, IndiaDepartment of Medical Oncology, Clinical Research Center, Manipal Hospital, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, IndiaDepartment of Medical Oncology, Hemato Oncology Clinic Ahmedabad Private Limited, Ahmedabad, Gujarat, IndiaDepartment of Oncology and Surgical Oncology, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, IndiaDepartment of Medical Research, Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Tata Memorial Hospital, Dr. Ernest Borges Marg, Mumbai, IndiaDepartment of Medical Oncology, King George Hospital, Visakhapatnam, Andhra Pradesh, IndiaDepartment of Medical Oncology, Indraprastha Apollo Hospitals, New Delhi, IndiaDepartment of Pathology, Tata Memorial Hospital, Dr. Ernest Borges Marg, Mumbai, IndiaDepartment of Medical Oncology, Tata Memorial Hospital, Dr. Ernest Borges Marg, Mumbai, IndiaDepartment of Medical Oncology, Tata Memorial Hospital, Dr. Ernest Borges Marg, Mumbai, IndiaDepartment of Medical Oncology, Tata Memorial Hospital, Dr. Ernest Borges Marg, Mumbai, IndiaMedical Department, Roche Products (India) Pvt. Ltd., Bandra Kurla Complex, Mumbai, IndiaMedical Department, Roche Products (India) Pvt. Ltd., Bandra Kurla Complex, Mumbai, IndiaContext: Trends in epidermal growth factor receptor (EGFR) mutation based on ethnicity assist the initial selection of targeted therapy regimen. Reported incidence of EGFR mutation in Indian NSCLC patients is variable, ranging from 22% to 51.8%. Aim and Settings and Design: This multicenter, noninterventional study evaluated the prevalence of EGFR mutation in Indian NSCLC patients, its association with patients’ demographics, and for the first time used a central laboratory for molecular testing. Subjects and Methods: Tissue samples from 252 NSCLC patients were tested at a Central Laboratory at Tata Memorial Hospital. Statistical Analysis Used: Patient demographics, baseline characteristics including smoking status from routine examination were recorded in a single visit. Chi-square or Fisher's exact test was used for association of EGFR mutation status with gender, age, smoking status, and histological subtypes. Results: The prevalence of EGFR mutation in Indian NSCLC patients was 23.4%. Among these, 55.9% patients had mutations in exon 19, 39% in exon 21, and 1.7% in exon 18. The incidence of EGFR mutation was higher in females than males (32.5% vs. 18.9%, respectively), and in 30.6% patients that had never smoked, 26.3% smokers, and 5.8% former smokers. The mean duration of transportation of tissue samples to the central laboratory was 48 h with an average turnaround time of 5 days for molecular testing. Conclusions: Molecular testing at a central laboratory is a feasible option in India. Prevalence of EGFR mutation in Indian NSCLC patients was similar across western and southern centers in India. A statistically significant association between EGFR mutation and gender as well as the smoking status of the patients was observed. Majority of the patients had in-frame deletions in exon 19.http://www.thieme-connect.de/DOI/DOI?10.4103/ASJO.ASJO_104_16epidermal growth factor receptor mutationnonsmall cell lung cancertyrosine kinase inhibitorindia |
| spellingShingle | Kumar Prabhash Amit Rauthan Senthil Rajappa Chirag Desai Rajesh Mistry Amit Dutt Anuradha Chougule Ravi Mohan Pratap K Das Rajiv Kumar Vanita Noronha Amit Joshi Vijay M Patil Binay Swarup Anil Kukreja Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test Asian Journal of Oncology epidermal growth factor receptor mutation nonsmall cell lung cancer tyrosine kinase inhibitor india |
| title | Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test |
| title_full | Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test |
| title_fullStr | Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test |
| title_full_unstemmed | Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test |
| title_short | Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test |
| title_sort | feasibility of molecular testing in a multicenter study with geographical variation in india epidermal growth factor receptor mutation as a model molecular test |
| topic | epidermal growth factor receptor mutation nonsmall cell lung cancer tyrosine kinase inhibitor india |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/ASJO.ASJO_104_16 |
| work_keys_str_mv | AT kumarprabhash feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT amitrauthan feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT senthilrajappa feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT chiragdesai feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT rajeshmistry feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT amitdutt feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT anuradhachougule feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT ravimohan feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT pratapkdas feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT rajivkumar feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT vanitanoronha feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT amitjoshi feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT vijaympatil feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT binayswarup feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest AT anilkukreja feasibilityofmoleculartestinginamulticenterstudywithgeographicalvariationinindiaepidermalgrowthfactorreceptormutationasamodelmoleculartest |